Concepedia

Author

Christine Roy-Duval

Sanofi (France)

Also Known As

C. Roy-Duval, C. Roy-duval, Christine Roy-Duval

8

Publications

572

Citations

4

H-Index

0

Concepts

All Affiliations

Sanofi (France)Sanofi (United States)Dallas Diabetes Research Center
CR

About

Christine Roy-Duval is an author at Sanofi (France).

Christine Roy-Duval

×

3

Publications

420

Citations

3

H-Index

YearCitations

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

Juris J. Meier, Julio Rosenstock, Agnès Hincelin-Méry,

Diabetes Care

2015

255

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial

Julio Rosenstock, Bruno Guerci, M Hanefeld,

Diabetes Care

2016

129

Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial

Graydon S. Meneilly, Christine Roy-Duval, Hasan Alawi,

Diabetes Care

2017

36

Page 1